CureVac N.V. (5CV.F)
EUR 3.15
(-2.48%)
EUR 3.15
(-2.48%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 41.85 Million EUR | -0.54% |
| 2022 | 42.08 Million EUR | 45.67% |
| 2021 | 28.89 Million EUR | -3.97% |
| 2020 | 30.08 Million EUR | -61.99% |
| 2019 | 79.14 Million EUR | 102689.61% |
| 2018 | 77 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 39.05 Million EUR | -3.95% |
| 2024 Q1 | 40.64 Million EUR | -2.91% |
| 2023 Q2 | 40.48 Million EUR | -1.61% |
| 2023 FY | 41.85 Million EUR | -0.54% |
| 2023 Q1 | 41.14 Million USD | -2.24% |
| 2023 Q3 | 42.11 Million EUR | 4.03% |
| 2023 Q4 | 41.85 Million EUR | -0.61% |
| 2022 Q3 | 41.26 Million EUR | 2.62% |
| 2022 Q2 | 40.2 Million EUR | -1.11% |
| 2022 Q1 | 40.65 Million EUR | 40.73% |
| 2022 FY | 42.08 Million EUR | 45.67% |
| 2022 Q4 | 42.08 Million EUR | 2.0% |
| 2021 Q4 | 28.89 Million EUR | -48.88% |
| 2021 Q3 | 56.52 Million EUR | 95.11% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 FY | 28.89 Million EUR | -3.97% |
| 2021 Q2 | 28.96 Million EUR | 0.0% |
| 2020 Q1 | 99.48 Million EUR | 25.7% |
| 2020 Q4 | 30.08 Million EUR | -1.82% |
| 2020 Q3 | 30.64 Million EUR | 0.0% |
| 2020 Q2 | - EUR | -100.0% |
| 2020 FY | 30.08 Million EUR | -61.99% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | 79.14 Million EUR | 102689.61% |
| 2019 Q4 | 79.14 Million EUR | 0.0% |
| 2018 FY | 77 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BioNTech SE | 219.1 Million EUR | 80.895% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | 93.932% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | 93.932% |
| BRAIN Biotech AG | 4.65 Million EUR | -798.443% |
| Formycon AG | 29.48 Million EUR | -41.961% |
| Heidelberg Pharma AG | 5.83 Million EUR | -617.815% |
| Medigene AG | 2.95 Million EUR | -1318.932% |